Trump meets with
big pharma CEOs and issues a list of demands.
Not exact matches
Reuters is out with a
big piece on the
big changes planned at U.K.
pharma giant GlaxoSmithKline under new
CEO Emma Walmsley — including substantial budget demands.
Valeant
CEO Mike Pearson said in a conference call that Medicis will strengthen the company's place in medical dermatology and bring it to critical mass in aesthetics, a $ 12 - billion market that doesn't depend on government health - plan reimbursement and previously did not have a significant «
big pharma» presence.
He wasn't surprised that startup
CEOs spoke up while the major players did not: «There are a lot more ways for the Trump administration to hurt
Big Pharma firms with products on the market than there are ways for the Trump administration to hurt biotech firms.»
The investment syndicate includes complementary parties such as international investors specialized in orphan drugs and corporate investors from
big pharma as well as specialty
pharma,» said Marc Martinell,
CEO and co-founder of Minoryx Therapeutics.
US: Heather Bresch, the
CEO of Mylan, an American pharmaceuticals company, finds herself at the center of one of the
biggest pharma controversies in recent years: price - gouging.